Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis

BACKGROUND: The mainstay of treatment for eosinophilic granulomatosis with polyangiitis (EGPA) is systemic corticosteroid therapy; some patients also receive intravenous immunoglobulins, other immunosuppressive agents, and biologics. Mepolizumab, an anti-interleukin-5 monoclonal antibody, induces re...

Descripción completa

Detalles Bibliográficos
Autores principales: Masumoto, Nami, Oshikata, Chiyako, Nakadegawa, Ryo, Motobayashi, Yuto, Osada, Reeko, Manabe, Saki, Kaneko, Takeshi, Tsurikisawa, Naomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182616/
https://www.ncbi.nlm.nih.gov/pubmed/37179316
http://dx.doi.org/10.1186/s13223-023-00801-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182616/
https://www.ncbi.nlm.nih.gov/pubmed/37179316
http://dx.doi.org/10.1186/s13223-023-00801-7

Ejemplares similares